# Rgenta Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rgenta-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Woburn, US
- Website: www.rgentatx.com
- Total disclosed funding: $98M
- Latest round: Series A (May 8, 2023)
- Investors on record: 10

## About

Rgenta Therapeutics, Inc. is a US-based biotechnology company that develops RNA-targeting small molecule therapies to treat previously undruggable diseases, focusing on oncology and central nervous system disorders.Founded in 2018, Rgenta Therapeutics, Inc. is headquartered in Woburn, US. The company specializes in the development of RNA-targeting therapies. The founders include Simon Xi, Travis Wager, and Zhiping Weng, with Simon Xi serving as the CEO. Rgenta has successfully completed 5 funding deals, with the most recent being a Series A round on May 8, 2023, which raised USD 8.00 mn from HighLight Capital. This round marks the total amount raised by the company as USD 8.00 mn, leading to a current company valuation of USD 110.039 mn.Rgenta Therapeutics focuses on innovative RNA-targeting small molecule therapies aimed at treating complex diseases, particularly in oncology and central nervous system disorders. Their offerings include small molecules that modulate RNA interactions to regulate splicing and gene expression. These therapies are designed to address high-impact areas such as solid tumors and genetic disorders, with initial applications including Huntington’s disease. The company targets distribution primarily in North America and Europe, serving hospitals, clinics, and research institutions dealing with challenging patient conditions.Rgenta Therapeutics generates revenue through collaborations with stakeholders in healthcare and pharmaceuticals, including biotechnology firms and academic institutions. Their revenue structure is based on milestone payments, research funding, and potential royalties from product sales. They engage clients through licensing agreements to access their proprietary RNA-targeting technology and products. Specific pricing plans for individual offerings are not publicly disclosed; however, the revenue model supports the ongoing development of key products addressing critical medical needs, ensuring sustainability in operations.In May 2023, Rgenta Therapeutics raised USD 8 million in Series A funding, which will be utilized to bolster research and development efforts. The company plans to continue developing RNA-targeting therapies and aims to expand its market presence in North America and Europe, with specific initiatives targeting areas of high unmet medical need. New products are in the design stage, and Rgenta is focused on advancing their therapeutic applications to launch in the coming years.

## Funding rounds

- Series A, May 8, 2023, $8M — HighLight Capital
- Series A, Nov 29, 2022, $52M — Delos Capital, Astra Zeneca CICC Healthcare Venture Capital Fund, Korean Investment Partners
- Seed, May 25, 2021, $18M — Vivo Capital, Lilly Asia Ventures, Kaitai Capital
- Seed, Apr 2, 2020, $20M — Boehringer Ingelheim Venture, Kaitai Capital, Legend Star, MPC

## Investors

- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Seed
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Seed
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Seed
- MPC — Seed
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Seed
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Seed
- Delos Capital (https://capitalatlas.ai/funds/delos-capital) — Series A
- Astra Zeneca CICC Healthcare Venture Capital Fund — Series A
- Korean Investment Partners — Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A